This session will spotlight Harmony-HHT, a global Phase 1/2 clinical trial recently initiated in the United States by Atavistik Bio. ATV-1601 is a novel oral investigational therapy under development in the Harmony-HHT Study.

In this webinar, Dr. Hanny Al-Samkari (Director of the Massachusetts General Brigham HHT CoE) and Dr. Susan Pandya (Chief Medical Officer of Atavistik Bio) will introduce ATV-1601, share key data supporting ATV-1601’s therapeutic potential, and provide an overview of the Harmony-HHT trial. The overview of Harmony-HHT will include a discussion of how patient feedback was instrumental in designing the trial, details on who is eligible to participate in this exciting new study, and how to access participating centers.

Register to attend